Skip to main content
Premium Trial:

Request an Annual Quote

Schering-Plough Licenses Oncomethylome Sciences Assay to Study Temodar Therapy

NEW YORK, Nov. 16 (GenomeWeb News) - Schering-Plough will license pharmacogenomic assay technology from Oncomethylome Sciences to study DNA methylation status in brain cancer patients, the companies said today.

 

Schering-Plough will pay OMS an upfront license payment, milestone payments, and sample processing fees. Actual amounts were not disclosed. 

 

Under the agreement, Schering-Plough will receive a worldwide non-exclusive license to use the assays and technology to measure the methylation status of the MGMT gene in brain cancer patients being treated with its drug Temodar. The collaboration will focus on glioblastoma multiforme brain cancer, but can potentially expand to other cancers and products.

 

OMS is a privately held company based in Belgium.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.